Pharsight

Vyondys 53 patents expiration

VYONDYS 53's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10968450 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(1 year, 8 months from now)

US10421966 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(1 year, 8 months from now)

US9994851 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(1 year, 8 months from now)

US9024007 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(1 year, 8 months from now)

US10227590 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(1 year, 8 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10266827 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(1 year, 8 months from now)

US10995337 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(1 year, 8 months from now)

USRE47691 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(1 year, 8 months from now)

Vyondys 53 is owned by Sarepta Theraps Inc.

Vyondys 53 contains Golodirsen.

Vyondys 53 has a total of 8 drug patents out of which 0 drug patents have expired.

Vyondys 53 was authorised for market use on 12 December, 2019.

Vyondys 53 is available in solution;intravenous dosage forms.

Vyondys 53 can be used as treatment of duchenne muscular dystrophy (dmd) in patients having a confirmed mutation of the dmd gene that is amenable to exon 53 skipping.

Drug patent challenges can be filed against Vyondys 53 from 2023-12-13.

The generics of Vyondys 53 are possible to be released after 12 December, 2026.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 12, 2026
New Chemical Entity Exclusivity (NCE) Dec 12, 2024

Drugs and Companies using GOLODIRSEN ingredient

NCE-1 date: 2023-12-13

Market Authorisation Date: 12 December, 2019

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients having a confirmed mutation of the dmd gene that is amenable to exon 53 skipping

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

VYONDYS 53 family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic